ACELYRIN, Inc. has announced its confidence in a proposed merger with Alumis Inc., scheduled for a stockholder vote on May 13, 2025. The merger aims to create a leading clinical-stage immunology company with a diversified portfolio of product candidates. ACELYRIN's Board of Directors emphasizes that the merger represents the culmination of a comprehensive and competitive process designed to maximize value for all stockholders. ACELYRIN stockholders are expected to retain approximately 48% ownership in the combined company, providing them with significant potential upside. The Board encourages stockholders to focus on the long-term benefits of the merger.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。